BioSpace News Archive

ReAlta Life Sciences, Inc. (“ReAlta”) a clinical stage, rare disease company addressing life-threatening diseases through harnessing the power of the immune system, today announced the dosing of the first patient in its Phase 1b Inhaled- lipopolysaccharide (LPS) challenge clinical trial in healthy volunteers to support development of RLS-0071 in severe asthma.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing single molecule protein sequencing, announced that Brian Reed, Ph.D., Head of Research at Quantum-Si, presented an update on the Company’s technology advancements at the Next-Generation Protein Analysis and Detection Conference.

ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will present at the William Blair Growth Stock Conference on Wednesday, June 8, 2022, beginning at approximately 9:20 a.m. (Central Daylight Time) at the Loews Chicago Hotel in Chicago.

Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced its first full analysis publication from the CAMEO (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes) registry that evaluated KENGREAL® (cangrelor) use and transition to oral P2Y12 inhibitors in routine clinical practice.

TransCode Therapeutics, Inc. announced that it was awarded the second tranche of funding from a Fast-Track Small Business Innovation Research grant from the National Cancer Institute of the NIH.

Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from Cohort I of their Phase I clinical trial.

GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells therapies for autoimmunity, autoinflammation and allergic diseases, announced that Neely Mozaffarian, M.D., Ph.D., has been appointed to the position of Chief Medical Officer.

Lucira has submitted for FDA emergency use authorization (EUA), with plans to introduce this new test as the nation adapts to an endemic coronavirus coincident with seasonal flu viruses.

Trethera Corporation (“Trethera”), announces that an independent safety review committee has unanimously recommended further trial advancement following review of the favorable results from the company’s Phase 1a dose escalation clinical trial of TRE-515, its first-in-class deoxycytidine kinase (“dCK”) inhibitor.

Presenters will explain how long-term and whole-cell hepatocyte models can be used to improve in-vitro in-vivo correlation predictions and advance drug discovery and development research.